# APPLE (NCT02856893)

> Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

No report yet. It can be ordered.

- Drugs tested: osimertinib; osimertinib plus gefitinib
- Indication: advanced EGFR-mutant NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02856893
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: NSCLC
- Interventions: Osimertinib; Gefitinib
- Enrollment: 156
- Primary outcome: PFS Rate at 18 Months

## Indexed commentary on APPLE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=apple-nct02856893